Werbung
Werbung

PRME

PRME logo

Prime Medicine, Inc. Common Stock

3.93
USD
Gesponsert
+0.01
+0.23%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

3.97

+0.04
+1.04%

PRME Ergebnisberichte

Positives Überraschungsverhältnis

PRME übertreffen die 3 der letzten 12Schätzungen.

25%

Nächster Bericht

Datum des nächsten Berichts
26. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.35M
/
-$0.25
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+92.11%
/
-21.88%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+7.80%
/
-19.35%

Prime Medicine, Inc. Common Stock earnings per share and revenue

On 07. Nov. 2025, PRME reported earnings of -0.32 USD per share (EPS) for Q3 25, missing the estimate of -0.25 USD, resulting in a -23.98% surprise. Revenue reached 1.23 million, compared to an expected 1.05 million, with a 17.04% difference. The market reacted with a -8.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 2.35 million USD, implying an decrease of -21.88% EPS, and increase of 92.11% in Revenue from the last quarter.
FAQ
For Q3 2025, Prime Medicine, Inc. Common Stock reported EPS of -$0.32, missing estimates by -23.98%, and revenue of $1.23M, 17.04% above expectations.
The stock price moved down -8.85%, changed from $4.18 before the earnings release to $3.81 the day after.
The next earning report is scheduled for 26. Feb. 2026.
Based on 14 analysts, Prime Medicine, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of $2.35M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung